Moderna and Merck said on Tuesday their experimental personalized vaccine continued to cut the risk of death or recurrence of ...

Moderna and Merck’s cancer vaccine reduced the risk of relapse or death for melanoma patients, five-year data from a Phase 2b ...

A combination of intismeran autogene and Keytruda significantly prolonged recurrence-free survival in melanoma.

The five-year results come from a phase 2b study that tested intismeran autogene in combination with Merck’s Keytruda in ...

Moderna and Merck shared five-year study data showing their combined cancer treatment cut the risk of melanoma coming back or ...

The companies have an expansive clinical program for the mRNA neoantigen therapy intismeran autogene in combination with ...

A large observational study using US healthcare claims and electronic health record data suggests that Moderna’s updated 2024 ...

Moderna pivots to infectious disease & oncology, targeting cash break-even by 2028. Click here to see why I rate MRNA stock a ...

Moderna CEO Stéphane Bancel positions 2026 as a catalyst-rich year driven by new vaccine launches, late-stage oncology data, ...

Moderna said on Monday it expects to report around $1.9  billion in sales for 2025, putting it near the upper end of its ...

Moderna said Wednesday that its experimental mRNA-based seasonal flu vaccine generated a stronger immune response against four strains of the flu virus than a currently marketed vaccine in a Phase 3 ...

Jan 20 () - Moderna ​and Merck ‌said on ‌Tuesday their experimental vaccine for ⁠a ‌serious type of ‍skin cancer, used in ...